Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1982 1
1987 1
1990 1
1993 1
1994 1
1995 1
1996 1
1997 2
1998 5
1999 1
2000 1
2001 1
2002 2
2003 2
2004 2
2005 3
2006 2
2007 1
2008 2
2009 4
2011 6
2012 2
2013 4
2014 13
2015 8
2016 6
2017 8
2018 6
2019 8
2020 5
2021 1
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Long-term changes of ionotropic glutamate and GABA receptors after unilateral permanent focal cerebral ischemia in the mouse brain.
Qü M, Mittmann T, Luhmann HJ, Schleicher A, Zilles K. Qü M, et al. Neuroscience. 1998 Jul;85(1):29-43. doi: 10.1016/s0306-4522(97)00656-8. Neuroscience. 1998. PMID: 9607700
Long-term hyperexcitability was found after unilateral, permanent middle cerebral artery occlusion in exofocal neocortical areas of the adult mouse [Mittmann et al. (1998) Neuroscience 85, 15-27]. The aim of the present study was to test the hypothesis in an identical para …
Long-term hyperexcitability was found after unilateral, permanent middle cerebral artery occlusion in exofocal neocortical areas of the adul …
Rapid review methods more challenging during COVID-19: commentary with a focus on 8 knowledge synthesis steps.
Tricco AC, Garritty CM, Boulos L, Lockwood C, Wilson M, McGowan J, McCaul M, Hutton B, Clement F, Mittmann N, Devane D, Langlois EV, Abou-Setta AM, Houghton C, Glenton C, Kelly SE, Welch VA, LeBlanc A, Wells GA, Pham B, Lewin S, Straus SE. Tricco AC, et al. J Clin Epidemiol. 2020 Oct;126:177-183. doi: 10.1016/j.jclinepi.2020.06.029. Epub 2020 Jun 29. J Clin Epidemiol. 2020. PMID: 32615209 Free PMC article. Review. No abstract available.
High-Cost Patients and Preventable Spending: A Population-Based Study.
de Oliveira C, Cheng J, Chan K, Earle CC, Krahn M, Mittmann N. de Oliveira C, et al. J Natl Compr Canc Netw. 2020 Jan;18(1):23-31. doi: 10.6004/jnccn.2019.7342. J Natl Compr Canc Netw. 2020. PMID: 31910386
Sociodemographic and clinical characteristics were examined and the costs of preventable acute care for both groups by category of visit/condition were estimated using validated algorithms. RESULTS: Compared with NHC patients with cancer (n=369,422), HC patients with cance …
Sociodemographic and clinical characteristics were examined and the costs of preventable acute care for both groups by category of visit/con …
Healthcare and Cancer Treatment Costs of Breast Screening Outcomes among Higher than Average Risk Women.
Mittmann N, Blackmore KM, Seung SJ, Diong C, Done SJ, Chiarelli AM. Mittmann N, et al. Curr Oncol. 2023 Sep 18;30(9):8550-8562. doi: 10.3390/curroncol30090620. Curr Oncol. 2023. PMID: 37754535 Free PMC article.
Healthcare costs were compared overall and 1 year after a false positive (n = 46,081) screening mammogram and 2 years after a breast cancer diagnosis (n = 6011). ...
Healthcare costs were compared overall and 1 year after a false positive (n = 46,081) screening mammogram and 2 years after a breast …
"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management.
Shickh S, Oldfield LE, Clausen M, Mighton C, Sebastian A, Calvo A, Baxter NN, Dawson L, Penney LS, Foulkes W, Basik M, Sun S, Schrader KA, Regier DA, Karsan A, Pollett A, Pugh TJ, Kim RH, Bombard Y; CHARM Consortium. Shickh S, et al. Oncologist. 2022 May 6;27(5):e393-e401. doi: 10.1093/oncolo/oyac039. Oncologist. 2022. PMID: 35385106 Free PMC article.
RESULTS: Thirty-five professionals participated and included genetic counselors (n = 12), geneticists (n = 9), oncologists (n = 4), family doctors (n = 3), lab directors and scientists (n = 3), a health-system decision maker, a surgeon, a pathol …
RESULTS: Thirty-five professionals participated and included genetic counselors (n = 12), geneticists (n = 9), oncologists ( …
MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.
Zhang L, Wang J, Wang Y, Zhang Y, Castro P, Shao L, Sreekumar A, Putluri N, Guha N, Deepak S, Padmanaban A, Creighton CJ, Ittmann M. Zhang L, et al. Cancer Res. 2016 Nov 1;76(21):6290-6298. doi: 10.1158/0008-5472.CAN-16-0087. Epub 2016 Aug 30. Cancer Res. 2016. PMID: 27578002 Free PMC article.
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V, Luo J, Parmar A, Dai WF, Beca JM, Raphael MJ, Isaranuwatchai W, Habbous S, Tadrous M, Earle CC, Biagi JJ, Mittmann N, Arias J, Gavura S, Chan KKW. Arciero V, et al. JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac047. doi: 10.1093/jncics/pkac047. JNCI Cancer Spectr. 2022. PMID: 35758620 Free PMC article.
Sensitivity analysis was conducted using the propensity score matching method. RESULTS: A total of 1988 patients were identified (Gem-Nab: n = 928; FOLFIRINOX: n = 1060). Mean survival was lower for patients in the Gem-Nab than the FOLFIRINOX group (0.98 vs 1.26 lif …
Sensitivity analysis was conducted using the propensity score matching method. RESULTS: A total of 1988 patients were identified (Gem-Nab: …
The economic impact of the transition from branded to generic oncology drugs.
Cheung WY, Kornelsen EA, Mittmann N, Leighl NB, Cheung M, Chan KK, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. Cheung WY, et al. Curr Oncol. 2019 Apr;26(2):89-93. doi: 10.3747/co.26.4395. Epub 2019 Apr 1. Curr Oncol. 2019. PMID: 31043808 Free PMC article.
RESULTS: The four randomized controlled trials included (representing 1979 patients) were cctg br.10 (early lung cancer, adjuvant vinorelbine-cisplatin vs. observation, n = 172), cctg br.21 (metastatic lung cancer, erlotinib vs. placebo, n = 731), cctg co.17 (metast …
RESULTS: The four randomized controlled trials included (representing 1979 patients) were cctg br.10 (early lung cancer, adjuvant vinorelbin …
"I just wanted more": Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screening.
Adi-Wauran E, Clausen M, Shickh S, Gagliardi AR, Denburg A, Oldfield LE, Sam J, Reble E, Krishnapillai S, Regier DA, Baxter NN, Dawson L, Penney LS, Foulkes W, Basik M, Sun S, Schrader KA, Karsan A, Pollett A, Pugh TJ; CHARM consortium; Kim RH, Bombard Y. Adi-Wauran E, et al. Eur J Hum Genet. 2024 Feb;32(2):176-181. doi: 10.1038/s41431-023-01473-y. Epub 2023 Oct 11. Eur J Hum Genet. 2024. PMID: 37821757
Participants were purposively sampled adult HCS patients recruited from a Canadian HCS research consortium. Thirty HCS patients were interviewed (n = 19 women, age range 20s-70s, n = 25 were white). Participants were highly concerned about developing cancers, partic …
Participants were purposively sampled adult HCS patients recruited from a Canadian HCS research consortium. Thirty HCS patients were intervi …
101 results